secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0001104659-21-142198
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics CFO Thomas Leggett resigns; Fang Ni named interim CFO
--------------------------------------------------------------------------------

- CFO Thomas Leggett resigned effective Nov 16, 2021, not due to any disagreement; will stay until Dec 3 for transition.
- Board appointed Fang Ni, Pharm.D., Chief Business Officer, as Interim CFO and principal financial officer effective Nov 19.
- Erika Jones, VP Finance and Corporate Controller, appointed principal accounting officer effective same date.
- Ni's base salary $388,100, eligible for up to 40% annual bonus; severance includes lump sum equal to base salary.
- Resignation and appointments are part of planned succession; no family relationships or conflicts reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/0001104659-21-142198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465921142198/tm2133581d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-142198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer